share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K：诺和诺德-股票回购计划
美股SEC公告 ·  10/07 07:58

Moomoo AI 已提取核心信息

Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The program, which began on August 7, 2024, is part of a larger 12-month initiative to buy back shares worth up to DKK 20 billion, starting from February 6, 2024. As of October 4, 2024, Novo Nordisk has repurchased 12,896,648 B shares at an average price of DKK 879.22 per share, totaling DKK 11,339,024,603. The transactions from September 30 to October 4, 2024, saw the acquisition of 225,464 B shares for DKK 177,760,424. Following these purchases, Novo Nordisk holds 14,225,279 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange. Novo Nordisk, founded in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The program, which began on August 7, 2024, is part of a larger 12-month initiative to buy back shares worth up to DKK 20 billion, starting from February 6, 2024. As of October 4, 2024, Novo Nordisk has repurchased 12,896,648 B shares at an average price of DKK 879.22 per share, totaling DKK 11,339,024,603. The transactions from September 30 to October 4, 2024, saw the acquisition of 225,464 B shares for DKK 177,760,424. Following these purchases, Novo Nordisk holds 14,225,279 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange. Novo Nordisk, founded in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.
全球领先的医疗保健公司诺和诺德报告了其股份回购计划的进展。该计划始于2024年8月7日，是一个为期12个月的更大倡议的一部分，旨在从2024年2月6日开始以高达200亿丹麦克朗的价格回购股份。截至2024年10月4日，诺和诺德已回购了128966480亿股，平均价格为879.22丹麦克朗/股，总金额达113,390,246,603丹麦克朗。 从2024年9月30日到10月4日的交易中，以177,760,424丹麦克朗的价格收购了2254640亿股。在此次购买之后，诺和诺德持有142252790亿股作为库存股，占股本的0.3%。 公司的股份在纳斯达克哥本哈根和纽约证券交易所进行交易。成立于1923年，总部位于丹麦的诺和诺德致力于对抗严重慢性疾病，并在全球约雇佣了约69,000名员工。
全球领先的医疗保健公司诺和诺德报告了其股份回购计划的进展。该计划始于2024年8月7日，是一个为期12个月的更大倡议的一部分，旨在从2024年2月6日开始以高达200亿丹麦克朗的价格回购股份。截至2024年10月4日，诺和诺德已回购了128966480亿股，平均价格为879.22丹麦克朗/股，总金额达113,390,246,603丹麦克朗。 从2024年9月30日到10月4日的交易中，以177,760,424丹麦克朗的价格收购了2254640亿股。在此次购买之后，诺和诺德持有142252790亿股作为库存股，占股本的0.3%。 公司的股份在纳斯达克哥本哈根和纽约证券交易所进行交易。成立于1923年，总部位于丹麦的诺和诺德致力于对抗严重慢性疾病，并在全球约雇佣了约69,000名员工。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间